Reference
- BENTLER, E., 1992, Cladribine (2-chlorodeoxyadenosine). Lancet, 340, 952–956.
- BENTLER, E., KOZIOL, J., MCMILLAN, R., SIPE, J. C., ROMINE, J. S. and CARRERA, C. J., 1994, Marrow suppression produced by repeated dose of cladribine. Acta Haematologica, 91, 10–15.
- BENTLER, E., PIRO, L. D. and SAYAN, A., 1991, 2-Chloro-2c-deoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia and Lymphoma, 5, 1–8.
- CARSON, D. A., KAYE, J. and SEEGMILLER, J. E., 1977, Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s). Proceedings of the National Academy of Sciences, USA, 74, 5677–5681.
- CARSON, D. A., WASSON, D. B. and BENTLER, B, 1984, Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proceedings of the National Academy of Sciences, USA, 81, 2232–2236.
- CARSON, D. A., WASSON, D. B., ESPARZA, L. M., CARRERA, C. J., KIPPS, T. J. and COTTAM, H. B., 1992, Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fiuoro-2'-deoxyadenosine. Proceedings of the National Academy of Sciences, USA, 89, 1970–1974.
- CARSON, D. A., WASSON, D. B., TEATLE, R. and Yu, A., 1983, Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytee. Blood, 62, 737–743.
- CHABNER, B. A., RYAN, D. P., PAZ-ARES, L., GARCIA-CARBONERO, R. and CALABRESI, P., 2001, Antineoplastic agents. In J. G. Hardman, L. E. Limbird and A. G. Gilman (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn (New York: McGraw-Hill), pp. 1389–1459.
- DE MIRANDA, P., BURNETT, T. and GOOD, S. S., 1990, Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metabolism and Disposition, 18, 315–320.
- LILIEMARK, J. and JuLiussoN, G., 1991, On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Research, 51, 5570–5572.
- LILIEMARK, J., ALBERTIONI, F., HASSAN, M. and JULIUSSON, G., 1992, On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology, 10, 1514–1518.
- MOYER, M. D., JOHANNSEN, T. and STUBBS, R. J., 1998. Determination of 2-chlorodeoxyadenosine (cladribine, 2-CdA) in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Pharmacological and Biomedical Analysis, 17, 45–51.
- RICE, G. P., FILIPPI, M. and Comi, G., 2000. Cladribine and progressive MS clinical and MRI outcomes of a multicenter controlled trial. Neurology, 54, 1145–1155.
- RISCOE, M. K., BROUNS, M. C. and FITCHEN, J. H., 1989. Purine metabolism is a target for leukemia chemotherapy. Blood Reviews, 3, 162–173.
- SAVEN, A., CHEUNG, W., SMITH, I., MOYER, M., JOHANNSEN, T., ROSE, E., GLLARD, R., KOSTY, M., MILLER, W. and PIRO, L., 1996, Pharmacokinetics study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy, Journal of Clinical Oncology, 14, 978–993. SAVEN, A. and PIRO, L. D., 1992, Treatment of hairy cell leukemia, Blood, 79, 1111–1120.
- SETO, S., CARRERA, C. J., KUBOTA, M., WASSON, D. B. and CARSON, D. A., 1985, Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. Journal of Clinical Investigation, 75, 377–378.
- SIPE, J. C., ROMINE, J. S., KOZIOL, J. A., MCMILLAN, R., ZYROFF, J. and BENTLER, E., 1994, Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 344, 9–13.
- Wu, W. N., McKowN, L. A. MOYER, M. D. and CHEUNG, W., 1999, The in vivo metabolism of cladribine in the mouse, monkey and human. ISSX Proceedings, 14, 91 (abst.comma; 7th European ISSX Meeting).